We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




SARS-Cov-2 Specific Antibody Responses in COVID-19 Patients

By LabMedica International staff writers
Posted on 30 Mar 2020
Print article
Image: Transmission electron micrograph of an isolate from a case of COVID-19, caused by the coronavirus SARS-CoV-2. The spherical viral particles, colorized blue, contain cross-sections through the viral genome, seen as black dots (Photo courtesy of Hannah A Bullock and Azaibi Tamin).
Image: Transmission electron micrograph of an isolate from a case of COVID-19, caused by the coronavirus SARS-CoV-2. The spherical viral particles, colorized blue, contain cross-sections through the viral genome, seen as black dots (Photo courtesy of Hannah A Bullock and Azaibi Tamin).
The rapid identification of the etiology and the sharing of the genetic sequence of the virus, followed by international collaborative efforts initiated due to the emergence of SARS-CoV-2 have led to the rapid availability of real-time PCR diagnostic assays that support the case ascertainment and tracking of the outbreak.

Validated serologic assays are crucial for patient contact tracing, identifying the viral reservoir hosts and for epidemiological studies. Epidemiological studies are urgently needed to help uncover the burden of disease, in particular, the rate of asymptomatic infections, and to get better estimates on morbidity and mortality.

An international team of scientists working with the Erasmus Medical Center (Rotterdam, the Netherlands) developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies. They used serum samples from patients with polymerase chain reaction (PCR)-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, and they validated and tested various antigens in different in-house and commercial enzyme-linked immunosorbent assays (ELISAs).

The investigators performed Anti-SARS-CoV-2 IgG and IgA ELISAs using beta-versions of two commercial kits (EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany). They performed the in-house ELISAs by coating 96-well microtiter ELISA plates with in-house produced spike antigens (S or S1 of SARS-CoV-2, SARS-CoV or MERS-CoV; or SARS-CoV-2 S1A, or RBD proteins) or SARS-N in PBS overnight at 4°C.After processing, the absorbance of each sample was measured at 450 nm.

The scientists demonstrated that most PCR-confirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs. They found that commercial S1 IgG or IgA ELISAs were of lower specificity while sensitivity varied between the two, with IgA showing higher sensitivity. They compared the performance of the different ELISAs for the detection of antibodies among PCR-confirmed COVID-19 patients to that of plaque reduction neutralization assay (PRNT), as the gold standard for CoV serology. PRNT50 correlated strongly with the different ELISAs, with the commercial IgA showing the strongest correlation followed by the S and N ELISAs indicating their capacity to detect SARS-CoV-2 specific antibodies.

The authors concluded that overall, the validated assays described here can be instrumental for the detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiological and vaccine evaluation studies. The study was published on March 20, 2020 in the pre-publications journal medRxiv.

Related Links:
Erasmus Medical Center
EUROIMMUN


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.